Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature [0.03%]
前列腺特异性膜抗原抑制剂在转移性前列腺癌诊断和治疗中的应用-专利文献综述
Hyunsoo Ha,Hongmok Kwon,Taehyeong Lim et al.
Hyunsoo Ha et al.
Introduction: Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for imaging and treatment of patients with prostate cancer because of its overexpression ...
Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020) [0.03%]
干扰素基因刺激剂激动剂作为抗肿瘤制剂的专利回顾（2008-2020）
Nan-Nan Chen,Han Zhang,Qi-Dong You et al.
Nan-Nan Chen et al.
Introduction: Stimulator of interferon genes (STING) is a transmembrane protein that localizes in the endoplasmic reticulum. As a crucial adaptor protein in the pathway of sensing cytosolic DNA, STING can regulate innate ...
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016-2020) [0.03%]
缺氧诱导因子(HIF)抑制剂专利盘点(2016-2020)
Hyun Seung Ban,Yoshikazu Uto,Hiroyuki Nakamura
Hyun Seung Ban
Introduction: Hypoxia-inducible factor (HIF) is a master regulator of oxygen homeostasis. The increased expression of genes targeted by HIF is associated with many human diseases, including ischemic cardiovascular disease, stroke, chronic l...
Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs [0.03%]
医药价格监管及其对药品创新的影响：缓解两难困境
Ashish Kumar Kakkar
Ashish Kumar Kakkar
Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease - a patent review (2016-present) [0.03%]
阿尔茨海默病的乙酰胆碱酯酶抑制剂治疗（2016-至今）专利回顾
Martina Bortolami,Daniele Rocco,Antonella Messore et al.
Martina Bortolami et al.
Introduction - AD, the most common form of dementia, has a multifactorial etiology, and the current therapy (AChEIs and memantine) is unable to interrupt its progress and fatal outcome. This is reflected in the research programs that are or...
Inventive step assessment of top selling monoclonal antibodies in Brazil [0.03%]
巴西畅销单克隆抗体的创造性评价分析研究
Louise Azulay Palavecino,Carlos Rangel Rodrigues,Murilo Lamim Bello et al.
Louise Azulay Palavecino et al.
Introduction: The patent system is fundamental for the pharmaceutical industry development, providing a return on the large investment of time and financial resources. Among the patentability requirements, understanding how to comply with t...
Soluble guanylate cyclase stimulators and their potential use: a patent review [0.03%]
可溶性鸟苷酸环化酶刺激剂及其潜在用途：专利回顾
Peter Sandner,Alexandros Vakalopoulos,Michael G Hahn et al.
Peter Sandner et al.
Introduction: In 2013, riociguat a potent and specific stimulator of the soluble guanylyl cyclase (sGC) was approved as first in class sGC stimulator which reflected a first culmination of intense research and development efforts starting i...
Malliga R Iyer,George Kunos
Malliga R Iyer
Introduction: Neurotensin is a gut-brain peptide hormone, a 13 amino acid neuropeptide found in the central nervous system and in the GI tract. The neurotensinergic system is implicated in various physiological and pathological processes re...
A patent review of transient receptor potential vanilloid type 1 modulators (2014-present) [0.03%]
2014年以来瞬时受体电位香草素亚型1调节剂的专利分析
Mengkang Gao,Yusui Wang,Lanqi Liu et al.
Mengkang Gao et al.
Introduction: Transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel with high permeability to calcium, which is widely expressed in the central nervous system (CNS) and peripheral nervous system. Since the TRPV1 ...
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present) [0.03%]
小分子DNA-PK抑制剂作为抗癌药物的研发（2010至今）——专利回顾
Suwen Hu,Zi Hui,Frédéric Lirussi et al.
Suwen Hu et al.
Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials.Are...